Durvalumab: Phase I/II started

The CVC Trials Network began an open-label, dose-escalation, international Phase I/II trial to evaluate subcutaneous motolimod ( VTX-2337), IV durvalumab and IV pegylated

Read the full 233 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE